Valeant Pharmaceuticals International Inc. Chief Executive Joseph Papa received compensation last year valued at $62.7 million, after the drug-industry veteran was tapped to take over the struggling drug company suffering from accounting problems, high debt levels and an image issue. Under Mr. Papa, the Canadian company has been working to sell off assets to sharpen the company’s focus on its key franchises in skin drugs, stomach...

Source: Wall Street Journal March 23, 2017 13:41 UTC